[{"indications": "Indications\u00a0\n(From Interferon gamma: British National Formulary)\nInterferon gamma", "name": "INTERFERON GAMMA-1b", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.4 Other immunomodulating drugs", "Interferon gamma", "INTERFERON GAMMA-1b"], "cautions": "Cautions\u00a0seizure disorders (including seizures associated with fever); cardiac\r\ndisease (including ischaemia, congestive heart failure, and arrhythmias); monitor before and during\r\ntreatment: haematological tests (including full blood count, differential\r\nwhite cell count, and platelet count), blood chemistry tests (including\r\nrenal and liver function tests) and urinalysis; avoid simultaneous administration of foreign proteins including immunological products (risk of exaggerated immune response); interactions: Appendix 1 (interferons)Driving\u00a0May impair ability to drive\r\nor operate machinery; effects may be enhanced\r\nby alcohol", "side-effects": "Side-effects\u00a0nausea, vomiting; headache, fatigue, fever; myalgia,\r\narthralgia; rash, injection-site reactions; rarely confusion and systemic lupus erythematosus; also reported, neutropenia,\r\nthrombocytopenia, and raised liver enzymes", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202811.htm", "doses": ["See under preparation", "By subcutaneous injection, 50\u00a0micrograms/m2 3 times a week; patients with body surface area of 0.5\u00a0m2 or less, 1.5\u00a0micrograms/kg 3 times a week; not yet recommended\r\nfor children under 6 months with chronic granulomatous disease"], "pregnancy": "Pregnancy\u00a0manufacturers recommend avoid unless potential benefit\r\noutweighs risk (toxicity in animal studies); effective\r\ncontraception required during treatment\u2014consult product literature"}]